Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of osteoporosis and bone density, published as a randomized controlled trial.

The aim of the study was to determine the effect of alendronate (ALN) on inflammatory markers and osteoprotegerin (OPG)/receptor activator of nuclear factor-kappaB ligand (RANKL), and to explore the associations of baseline systemic inflammation and vitamin D status on the bone mineral density (BMD) response to ALN.

Who Took Part

According to the abstract, 70 subjects were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Stored plasma samples in 70 subjects were assayed for levels of 25-hydroxyvitamin D (25(OH)D), OPG, RANKL, interleukin (IL)-6 and soluble receptors for tumour necrosis factor (TNF)-α 1 and 2 (sTNFR 1 and 2).

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The subjects were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the subjects nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Serum C-telopeptide (CTx) and BMD were assessed at baseline and week 48.

What Was Measured

PubMed files the paper under topics including Alendronate, Bone Density, Bone Density Conservation Agents, Bone Resorption, Cholecalciferol, HIV Infections and Lumbar Vertebrae.

The authors tagged it with the keywords bone turnover marker, inflammation, low bone mineral density and vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 70 subjects in people with osteoporosis and bone density.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (HIV medicine), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Osteoporosis and bone density research.